New drug trial aims to protect kidneys from rapid damage
NCT ID NCT06676579
Summary
This study is testing whether a drug called avacopan, given with a low dose of steroids, can help control a serious, fast-progressing form of kidney disease called crescentic IgA nephropathy. It will involve 16 adults with this condition to see if the treatment safely reduces protein in the urine and helps preserve kidney function over 12 months. The goal is to find a better way to manage this disease and slow its progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224, United States
Contact
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Conditions
Explore the condition pages connected to this study.